CLAIMS

1. An antisense oligonucleotide of 10 – 30 nucleotides in length, wherein said antisense oligonucleotide targets a HTRA1 nucleic acid, and comprises a contiguous nucleotide region wherein the contiguous nucleotide region is selected from the group selected from:

   TTCtatctacgcaTTG (SEQ ID NO 67),
   CTTCttctatctacgcAT (SEQ ID NO 73), and
   TACTttaatagcTCAA (SEQ ID NO 86);

   wherein capital letters are LNA nucleotides, and lower case letters are DNA nucleosides, and cytosine residues are optionally 5-methyl cytosine.

2. The antisense oligonucleotide according to claim 1, wherein the LNA nucleosides are beta-D-oxy LNA nucleosides.

3. The antisense oligonucleotide according to any one of claims 1 and 2, wherein the internucleoside linkages between the nucleotides of the contiguous nucleotide region are all phosphorothioate internucleotides linkages.

4. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:

   $T_sT_s{}^mC_st_sa_st_sc_st_sa_s{}^mc_sg_sc_sa_sT_sT_sG$ (SEQ ID NO 67,1),

   wherein capital letters represent beta-D-oxy LNA nucleosides, lower case letters are DNA nucleosides, subscript s represents a phosphorothioate internucleoside linkage, and ^mC represent 5 methyl cytosine beta-D-oxy LNA nucleosides, and ^mc represents 5 methyl cytosine DNA nucleosides; or a pharmaceutically acceptable salt thereof.

5. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:

   $^mC_sT_sT_s{}^mC_st_st_sc_st_sa_st_sc_st_sa_s{}^mc_sg_sc_sA_sT$ (SEQ ID NO 73,1),


   wherein capital letters represent beta-D-oxy LNA nucleosides, lower case letters are DNA nucleosides, subscript s represents a phosphorothioate internucleoside linkage, and ^mC represent 5 methyl cytosine beta-D-oxy LNA nucleosides, and ^mc represents 5 methyl cytosine DNA nucleosides; or a pharmaceutically acceptable salt thereof.

6. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:

$T_sA_s{}^mC_sT_st_st_sa_sa_st_sa_sg_sc_sT_s{}^mC_sA_sA$ (SEQ ID NO 86,1);


wherein capital letters represent beta-D-oxy LNA nucleosides, lower case letters are DNA nucleosides, subscript s represents a phosphorothioate internucleoside linkage, and ^mC represent 5 methyl cytosine beta-D-oxy LNA nucleosides, and ^mc represents 5 methyl cytosine DNA nucleosides; or a pharmaceutically acceptable salt thereof.

7. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:




or a pharmaceutically acceptable salt thereof.

8. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:



or a pharmaceutically acceptable salt thereof.

9. The antisense oligonucleotide according to claim 1, wherein the antisense oligonucleotide is:



or a pharmaceutically acceptable salt thereof.

10. The pharmaceutically acceptable salt of any one of the oligonucleotide of claims 1-9.

11. A conjugate comprising the oligonucleotide according to any one of claims 1 – 9, and at least one conjugate moiety covalently attached to said oligonucleotide.

12. A pharmaceutical composition comprising the oligonucleotide of claims 1 – 10 or the conjugate of claim 11 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

13. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition comprises a pharmaceutically acceptable diluent.

14. The pharmaceutical composition according to claim 13, wherein the pharmaceutically acceptable diluent is phosphate buffered saline.

15. The pharmaceutical composition according to any one of claims 12-14, wherein the oligonucleotide is in the form of a pharmaceutically acceptable salt.

16. The pharmaceutical salt of any one of claims 1 – 19, or the pharmaceutical composition according to claims 12-15, wherein the pharmaceutically acceptable salt is a sodium salt.

17. An i*n vitro* method for modulating HTRA1 expression in a target cell which is expressing HTRA1, said method comprising administering an oligonucleotide of any one of claims 1 – 10 or the conjugate according to claim 11 or the pharmaceutical composition of any one of claims 12 – 15 in an effective amount to said cell.

18. The oligonucleotide of any one of claims 1-10 or the conjugate according to claim 11 or the pharmaceutical composition of any one of claims 12-15 for use in medicine.

19. The oligonucleotide of any one of claims 1-10 or the conjugate according to claim 11 or the pharmaceutical composition of any one of claims 12 – 15 for use in the treatment or prevention of macular degeneration.

20. The oligonucleotide, conjugate or pharmaceutical compositionaccording to claim 19 wherein the use is for the treatment of wetAMD, dryAMD, geographic atrophy, intermediate dAMD or diabetic retinopathy.

21. Use of an oligonucleotide according to any one of claims 1 – 10 or the conjugate according to claim 11 or the pharmaceutical composition of any one of claims 12 – 15 in the manufacture of a medicament for the treatment or prevention of a macular degeneration in a subject.

22. The use according to claim 21, wherein the medicament is for the treatment of dryAMD, geographic atrophy, or intermediate dAMD.